PAI
VERV

Palo Alto Investors’s Verve Therapeutics VERV Stock Holding History

Palo Alto Investors’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-575,817
Closed -$2.63M – 50
2025
Q1 		$2.63M Hold
575,817
– – 0.5% 25
2024
Q4 		$3.25M Hold
575,817
– – 0.5% 23
2024
Q3 		$2.79M Hold
575,817
– – 0.36% 26
2024
Q2 		$2.81M Hold
575,817
– – 0.33% 27
2024
Q1 		$7.65M Hold
575,817
– – 0.86% 24
2023
Q4 		$8.03M Buy
+575,817
New +$7.14M 0.72% 22

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Palo Alto Investors's VERV Position: Q2 2025 in Review

Palo Alto Investors sold out of Verve Therapeutics (VERV) in Q2 2025, closing a stake of 575,817 shares — an estimated $2.63M sold.

Palo Alto Investors first reported a position in VERV in Q4 2023 and held it in 6 quarters. The position peaked at $8.03M in Q4 2023. 175 funds tracked by Wall St. Rank hold VERV as of Q2 2025.

  • Palo Alto Investors reported no remaining Verve Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Palo Alto Investors sold 575,817 Verve Therapeutics shares in Q2 2025, an estimated $2.63M.
  • Palo Alto Investors first reported a position in Verve Therapeutics in Q4 2023 and held it in 6 quarters.
  • Palo Alto Investors's Verve Therapeutics position peaked at $8.03M in Q4 2023.
  • 175 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2025.

Based on Palo Alto Investors's 13F filing for Q2 2025, filed 14 Aug 2025.